SCPH — Scpharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $304.36m
- $314.75m
- $36.33m
Annual income statement for Scpharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 13.6 | 36.3 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | 9.78 | 25 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 29.9 | 25.8 | 36.2 | 69 | 114 |
| Operating Profit | -29.9 | -25.8 | -36.2 | -55.4 | -77.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -32.2 | -28 | -36.8 | -54.8 | -85.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -32.2 | -28 | -36.8 | -54.8 | -85.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -32.2 | -28 | -36.8 | -54.8 | -85.1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -32.2 | -28 | -36.8 | -54.8 | -85.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.31 | -1.14 | -1.3 | -1.42 | -1.62 |